Biology:ExPEC4V
From HandWiki
ExPEC4V, also known as JNJ-63871860, is a vaccine against urinary tract infections (UTIs) and Escherichia coli infection.[1][2][3][4] It is an Escherichia coli polysaccharide conjugate vaccine.[1][2][4] The vaccine is administered by intramuscular injection.[2] It is being developed by GlycoVaxyn and Johnson & Johnson.[1] As of November 2023, ExPEC4V is in phase 2 clinical trials.[1] There is also a 10-valent form called ExPEC10V (VAC-52416; JNJ-69968054).[4][5] In February 2025 Johnson & Johnson stopped the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.[6]
See also
References
- ↑ 1.0 1.1 1.2 1.3 "JNJ 63871860". 5 November 2023. https://adisinsight.springer.com/drugs/800037300.
- ↑ 2.0 2.1 2.2 "The development and early clinical testing of the ExPEC4V conjugate vaccine against uropathogenic Escherichia coli". Clinical Microbiology and Infection 24 (10): 1046–1050. October 2018. doi:10.1016/j.cmi.2018.05.009. PMID 29803843.
- ↑ "Vaccines against extraintestinal pathogenic Escherichia coli (ExPEC): progress and challenges". Gut Microbes 16 (1). 2024. doi:10.1080/19490976.2024.2359691. PMID 38825856.
- ↑ 4.0 4.1 4.2 "It's Time to Embrace Vaccination as We Enter the Postantibiotic Era of Recurrent Urinary Tract Infection Management". The Journal of Urology 211 (6): 797–799. June 2024. doi:10.1097/JU.0000000000003969. PMID 38704743.
- ↑ "VAC 52416". 28 April 2023. https://adisinsight.springer.com/drugs/800053991.
- ↑ "J&J stops Phase III trial of Sanofi's E. Coli vaccine citing 'disappointing' results". February 13, 2025. https://www.clinicaltrialsarena.com/news/jj-stops-phase-iii-trial-of-sanofi-e-coli-vaccine-citing-disappointing-results/?cf-view.
 |  |
